Stoke Therapeutics (STOK) Stock Price, News & Analysis

Company Overview

Stoke Therapeutics, Inc. is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene. The company has also pursued additional TANGO-based programs for other genetic diseases, including conditions affecting the nervous system and vision.

Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke conducts research and clinical development activities through collaborations and clinical studies in the United States and other regions. The company is led by Edward Kaye, M.D., who serves as chief executive officer and has experience in the development of therapies for rare diseases.

Key Stats

• Today's Range: $23.45 to $24.62
• 50-Day Range: $22.50 to $33.46
• 52-Week Range: $20.32 to $40.22
• Volume: 691,893 shs
• Average Volume: 785,418 shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.25
• Consensus Rating: Moderate Buy

Stoke Therapeutics Stock Analysis - MarketRank™

Stoke Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 570th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Stoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Stoke Therapeutics has a consensus price target of $44.25, representing about 79.8% upside from its current price of $24.61.

Amount of Analyst Coverage

Stoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stoke Therapeutics are expected to grow in the coming year, from ($3.52) to ($3.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stoke Therapeutics is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stoke Therapeutics is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stoke Therapeutics has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.72% of the float of Stoke Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 10.17, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently increased by 3.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stoke Therapeutics does not currently pay a dividend.

Dividend Growth

Stoke Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.72

News Sentiment

Stoke Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Stoke Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,069,305.00 in company stock.

Percentage Held by Insiders

9.60% of the stock of Stoke Therapeutics is held by insiders.

Percentage Held by Institutions

Stoke Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:STOK
• CIK: 1623526
• Web: www.stoketherapeutics.com
• Phone: (781) 430-8200
• Fax: N/A
• Employees: 170
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Stoke Therapeutics: $44.25
• High Price Target: $60.00
• Low Price Target: $35.00
• Potential Upside/Downside: +79.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.89 million
• Net Margins: -753.60%
• Pretax Margin: -758.23%
• Return on Equity: -59.36%
• Return on Assets: -51.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.69
• Quick Ratio: 7.69

Sales & Book Value

• Annual Sales: $27.59 million
• Price / Sales: 57.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.17 per share
• Price / Book: 3.99

Miscellaneous

• Outstanding Shares: 64,526,000
• Free Float: 58,332,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 1.26